)

Vera Therapeutics (VERA) investor relations material
Vera Therapeutics Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key clinical developments
Lead product Atacicept showed strong results in Phase III for IgA nephropathy, with plans to file a BLA in Q4 and anticipated market entry by mid-next year.
Phase II and III data demonstrated consistent efficacy, including a 42% placebo-adjusted reduction in proteinuria and stabilization of GFR, surpassing FDA thresholds.
Long-term data showed patients on Atacicept could avoid dialysis or transplant, marking a transformative advance in kidney disease management.
Open-label extension studies are ongoing, with high patient enthusiasm and positive real-world experience using the auto-injector.
Monthly dosing studies and a new fusion protein (VT-109) are in progress to expand the product profile and dosing flexibility.
Market opportunity and commercialization
IgA nephropathy is a significant unmet need, with an estimated 160,000–200,000 US patients and a potential $10–20 billion market.
Diagnosis rates are expected to rise as new therapies become available, expanding the addressable market.
Commercial launch preparations are advanced, with sales leadership in place and strong engagement with the nephrology and patient communities.
The auto-injector is well received, offering convenient at-home administration and high patient retention over two years.
The company is leveraging synergies across clinical sites and capital efficiency for ongoing and future studies.
Regulatory and competitive landscape
BLA submission is on track for Q4, with no major gating factors and expectations for priority review.
Regulatory discussions are collaborative, and there is optimism for a competitive label based on the unique mechanism and robust data.
The company is closely monitoring competitor data but remains confident in its differentiated results and future market position.
Additional studies (PIONEER) are enrolling broader IgAN populations and exploring other autoimmune kidney diseases.
The pipeline includes plans to expand into membranous nephropathy, FSGS, MCD, and potentially other autoimmune indications.
Next Vera Therapeutics earnings date

Next Vera Therapeutics earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage